Monte Rosa Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 1 week.
- Its last 3 Sell calls were followed by a 23% average decline over the next quarter.
- Recent price momentum is -38.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 24.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -43.8% | Better than 9% |
| Net margin | -31.2% | Better than 11% |
| Return on equity | -16.9% | Better than 17% |
| Return on invested capital | -19.0% | Better than 14% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -39.6% | Better than 11% |
| 6-month return | -54.1% | Better than 6% |
| 12-month return (ex latest month) | -23.8% | Better than 13% |
| Distance below 52-week high | 66.5% | Better than 8% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.1x | Better than 89% |
| Debt to assets | 8.7% | Better than 72% |
| Interest coverage | -7,739.0x | Better than 1% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 191.0% | Better than 94% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 8.91
- Open
- 8.73
- Day range
- 8.48 - 9.04
- Avg price
- 8.67
- Volume
- 2.52M
- Turnover
- 21.85M
- Turnover ratei
- 4.43%
- Volume ratioi
- 2.26
- Amplitudei
- 6.29%
- 52-week rangei
- 8.48 - 25.77
Valuation
- P/Ei
- -18.78
- P/E (TTM)i
- -6.22
- P/Bi
- 1.49
- EPSi
- -0.46
- Book value / shi
- 5.81
- Net profit
- -39.31M
- Net assets
- 496.21M
Share structure
- Market cap
- 738.29M
- Float capi
- 491.52M
- Shares out
- 85.45M
- Float sharesi
- 56.89M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-06-24
66.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-10.84M net over the window
Short interest
- Shares short
- 20.86M
- % of floati
- 24.45%
- Days to coveri
- 15.68
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics last traded at 8.64. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Monte Rosa Therapeutics's market cap?
About 738.29M.
What is the P/E ratio of Monte Rosa Therapeutics?
The trailing twelve-month P/E is -6.22, below its own 5-year average of 2.60 — toward the bottom of its historical range (11.09% percentile). See the Valuation tab for the full history.
Does Monte Rosa Therapeutics pay a dividend?
Monte Rosa Therapeutics does not currently pay a regular dividend.
Is Monte Rosa Therapeutics a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 25.14, which implies 191.0% upside from the current price. This is not investment advice.
What is Monte Rosa Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Monte Rosa Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Monte Rosa Therapeutics discussion 0 comments